Immunotherapy treatment after chemotherapy significantly slows metastatic bladder cancer

Using immunotherapy immediately after chemotherapy treatment in patients with metastatic bladder cancer significantly slowed the progression of the cancer, according to results of a clinical trial led by Mount Sinai researchers published in the Journal of Clinical Oncology in April.

The study is the first to show that this approach to therapy, called switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. The randomized Phase 2 trial tested this treatment in 108 patients.

The trial tested an immunotherapy known as pembrolizumab after patients were treated with platinum-based chemotherapy in one group of patients and used a placebo after the same type of chemotherapy in a second group. The time until the cancer progressed was approximately 60 percent longer for the pembrolizumab group compared with the control group.

Source: Read Full Article

Related posts:
  1. Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial
  2. Lung-cancer patients will get access to a life-saving treatment
  3. Does HIV increase cancer risk? Types and treatment
  4. Cancer-stricken woman, 27, desperately tries to raise £500,000
  5. Immunotherapy combination generates responses against castration-resistant metastatic prostate cancer